## Endocarditis as a Sentinel Marker for New Epidemics of Injection Drug Use and Hepatitis C Virus Infection

Susana Williams Keeshin, MD, Judith Feinberg, MD Division of Infectious Disease University of Cincinnati



# Objectives

- Prevalence of injection drug use (IDU) is difficult to define
- Anecdotally, at The University Hospital, a tertiary care teaching hospital serving metropolitan Cincinnati, there appeared to be an increase in Infective Endocarditis (IE) over the past 10 years
- We sought to define the prevalence of IDU, HCV, and HIV among patients admitted to TUH with IE

## Methods


- Retrospective chart review
- Patients admitted for IE (Modified Dukes Criteria) from Jan. 1, 1999 Dec.31, 2009
- Chi-squared test used for all p values



## Results



# Endocarditis Admissions, HCV and Tox+ at TUH 1999-2009



#### Endocarditis Cases 1999-2009: Demographics

| Variable                                  | No. (%)     |
|---|-------------|
| Total                                     | 542         |
| Sex:                                      |             |
| Male                                      | 308 (57%)   |
| Race:                                     |             |
| White                                     | 319 (59%)   |
| Black                                     | 203 (37%)   |
| Other                                     | 20 (4%)     |
| Mean Age (SD), years                      | 50.6 (15.8) |
| Insurance:                                |             |
| Public                                    | 414 (76.4%) |
| Private                                   | 110 (20.3%) |
| *None                                     | 18 (3.3%)   |
| Mean length of hospitalization (SD), days | 14.6 (12)   |
| Length of hospitalization range, days     | (1-109)     |
| In-hospital mortality                     | 111 (28%)   |



## HIV, HCV and Toxicology Testing

| Variable          | No. (%)   |
|-------------------|-----------|
| HIV status        | 138 (25%) |
| Positive          | 28 (5%)   |
| Negative          | 110 (20%) |
| Not tested        | 404 (75%) |
| HCV status        | 175 (32%) |
| Positive          | 86 (16%)  |
| Negative          | 89 (16%)  |
| Not tested        | 367 (68%) |
| Toxicology Screen | 155 (28%) |
| Positive          | 106 (19%) |
| Negative          | 49 (9%)   |
| Not tested        | 387 (72%) |



### **Toxicology and IDU History**

|                  | Tox+     | Tox-     | Tox not tested | IDU+ by history | p value (btwn<br>Tox testing) |
|------------------|----------|----------|----------------|-----------------|-------------------------------|
| Total            | 106      | 49       | 387            | 108             |                               |
| Screened for HCV | 70 (66%) | 22 (45%) | 83 (21%)       | 75 (69%)        | <0.001                        |
| HCV positive     | 50 (71%) | 6 (27%)  | 30 (36%)       | 53 (71%)        | 0.019                         |
| Screened for HIV | 66 (62%) | 25 (51%) | 47 (12%)       | 72 (67%)        | <0.001                        |



## Conclusions

- Over a 10 year period there was a 2-fold increase in IE admissions, a 4fold increase in HCV prevalence and a 6-fold increase in known IDU by +toxicology screens, but no appreciable increase in +HIV tests
- This is an underestimation of the actual prevalence as most admissions were not screened for IDU, HCV and/or HIV
- The observation of a sharp increase in IE cases may be useful as a sentinel marker of new IDU and HCV epidemics
- IDU status needs to be assessed and screening for HCV and HIV performed among pts admitted for IE, both for optimal inpatient care and so that linkage to appropriate outpatient care can be implemented



## **Contact Information**

#### Susana Keeshin: willi2su@ucmail.uc.edu

